Progression of Mycosis Fungoides After Fingolimod Treatment for Multiple Sclerosis and Targeted Next-Generation Sequencing Demonstrating Potential Links Between the Two Diseases.

Abstract

Article Tools CASE REPORTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/PO.22.00501 JCO Precision Oncology no. 7 (2023) e2200501. Published online February 1, 2023. PMID: 36724412 Progression of Mycosis Fungoides After Fingolimod Treatment for Multiple Sclerosis and Targeted Next-Generation Sequencing Demonstrating Potential Links Between the Two Diseases Saisindhu Narala , MD, MAS1,2xSaisindhu NaralaSearch for articles by this author; Yonglu Che, MD, PhD2xYonglu CheSearch for articles by this author; Atif Saleem , DO1xAtif SaleemSearch for articles by this author; Christopher B. Lock , MBBS, PhD3xChristopher B. LockSearch for articles by this author; Youn H. Kim , MD2xYoun H. KimSearch for articles by this author; and Kerri E. Rieger , MD, PhD1,2xKerri E. RiegerSearch for articles by this author Show More 1Department of Pathology, Stanford University School of Medicine, Stanford, CA2Department of Dermatology, Stanford University School of Medicine, Stanford, CA3Division of Neuroimmunology, Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA https://doi.org/10.1200/PO.22.00501 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologySUPPORTSupported in part by the Haas Family Foundation (Y.H.K.).AUTHOR CONTRIBUTIONSConception and design: Saisindhu Narala, Youn H. Kim, Kerri E. RiegerProvision of study materials or patients: Youn H. KimCollection and assembly of data: Saisindhu Narala, Yonglu Che, Atif Saleem, Christopher B. Lock, Youn H. Kim, Kerri E. RiegerData analysis and interpretation: Saisindhu Narala, Yonglu Che, Youn H. Kim, Kerri E. RiegerManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Christopher B. LockEmployment: NeoTxStock and Other Ownership Interests: NeoTXHonoraria: TG TherapeuticsConsulting or Advisory Role: TG Therapeutics, Diagnose EarlySpeakers' Bureau: Bristol-Myers Squibb/MedarexTravel, Accommodations, Expenses: GenentechYoun H. KimConsulting or Advisory Role: Kyowa Hakko Kirin, Innate Pharma, Corvus Pharmaceuticals, Galderma, Crispr TherapeuticsResearch Funding: Eisai (Inst), Kyowa Hakko Kirin (Inst), Innate Pharma (Inst), Elorac Pharmaceuticals (Inst), Crispr Therapeutics (Inst), Corvus Pharmaceuticals (Inst)Patents, Royalties, Other Intellectual Property: Royalty for Chapters in UpToDateTravel, Accommodations, Expenses: Innate PharmaKerri E. RiegerConsulting or Advisory Role: Kyowa Kirin International, PfizerNo other potential conflicts of interest were reported.